Tempus AI Acquires Cancer-Monitoring Firm Personalis for $1.5 Billion
Tempus AI (NASDAQ:TEM) is acquiring cancer-monitoring company Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its presence in the minimal residual disease testing market. The transaction includes an offer of $16.25 per share for Personalis shareholders and builds on a prior partnership established between the two companies.
Topics: biotech cancer monitoring MRD tests NASDAQ